Nimefort (Nimesulide)

Nimesulide selectively inhibits cyclooxygenase‑2 (COX‑2), the enzyme responsible for converting arachidonic acid into prostaglandins that mediate pain, inflammation and fever. By reducing prostaglandin synthesis, it provides analgesic, antipyretic and anti‑inflammatory effects while sparing COX‑1 activity, which helps limit gastrointestinal side effects compared with non‑selective NSAIDs.

The specific dose of Nimefort is determined by the prescribing healthcare professional based on the patient’s condition, age, weight and response. Prescribers follow local guidelines and product labeling to select the appropriate strength and dosing interval, and patients should follow the instructions provided on the prescription label.

The safety of nimesulide in pregnancy and lactation has not been established, and it is generally contraindicated during the third trimester because of potential fetal risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider before using Nimefort.

To place an order, submit an inquiry on the product page at gnhindia.com specifying the desired quantity of Nimefort. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain or temperature control) and assistance with import documentation.

Nimefort (nimesulide) is a COX‑2‑selective NSAID, which may offer a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. However, it carries its own safety considerations, including potential liver toxicity, and its efficacy in pain and inflammation is comparable to other agents in the same therapeutic class.

Nimefort should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Nimefort is taken orally, usually with a full glass of water. It may be taken with or without food, but taking it with food can help reduce possible stomach discomfort. Patients should swallow the tablet whole and not split, crush or chew it unless directed by a healthcare professional.

The most serious risks include hepatotoxicity, which can manifest as elevated liver enzymes or liver failure, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Additionally, rare cases of renal impairment and serious gastrointestinal bleeding have been reported, especially when used with other NSAIDs or anticoagulants.

Nimefort should be avoided in individuals with known hypersensitivity to nimesulide or other NSAIDs, in patients with active peptic ulcer disease, severe liver or kidney impairment, and in those taking anticoagulants without medical supervision. It is also contraindicated during the third trimester of pregnancy and in children under the age specified in local labeling.